Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

← catalyst calendar

NCT04544293 · results posted

Sponsored by Savara Inc. (industry) · SVRA — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
164actual
Sites
54
Countries
Australia, Belgium, Canada +15

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2021-05-19actualWhen the study began enrolling
Primary completion2023-11-30actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2027-05-30estimatedThe whole study's end, after follow-up
First posted2020-09-10actualWhen this record first appeared on the registry
Results posted2025-08-07actualWhen the sponsor posted results to the registry
Record updated2025-08-07actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Autoimmune Pulmonary Alveolar Proteinosis

Interventions

  • Drug: Molgramostim — also filed as Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF)
  • Drug: Placebo — also filed as Placebo nebulizer
  • Drug: Molgramostim Open-label — also filed as Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF)

Primary outcome

what the primary-completion date above is the date OF
Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24
measured From Baseline to Week 24

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2024-10-09 · 4.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-04-24 · 4.6 MB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · SVRA's whole pipeline · Catalyst calendar · Every registered study · What changed